STOCK TITAN

Quest Diagnostics Inc. - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.

In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.

Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.

Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.

By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.

Rhea-AI Summary

Quest Diagnostics is partnering with the CDC to provide free COVID-19 testing at around 1,200 of its patient service centers for uninsured individuals. This initiative aims to enhance accessibility in communities heavily impacted by the pandemic. Eligible individuals must complete an online screening via QuestDirect and meet specific criteria, including symptoms or exposure. Previous collaborations between Quest and CDC have focused on public health initiatives, including variant sequencing and serology testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
partnership covid-19
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) will release its second quarter 2022 financial results on July 21, 2022, before market opening. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss these results. Participants can access the call by dialing the appropriate numbers based on their location. The earnings release and live webcast will be available on the company's investor relations website. Additionally, replays of the call will be accessible for a limited time post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
Rhea-AI Summary

A recent Quest Diagnostics study reveals the disparity in hepatitis C (HCV) screening among pregnant individuals in the U.S., particularly between those with Medicaid and commercial insurance. Although a 145% increase in screening was noted from 2011 to 2021, only 40.6% were screened by early 2021. The study highlights that those on Medicaid experienced lower screening rates, with only 18.4% receiving tests compared to 25% of those with commercial insurance. This underscores the urgent need for improved healthcare access and screening adherence for vulnerable populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) has appointed Sam Samad as Executive Vice President and Chief Financial Officer, replacing Mark Guinan, who announced his retirement after over eight years. Samad, who will join on July 11, 2022, previously served as CFO at Illumina and held senior roles at Cardinal Health and Eli Lilly. The transition will ensure continuity as Guinan remains until the second-quarter financial report. CEO-elect Jim Davis and Steve Rusckowski, Chairman, highlighted Samad's extensive experience and anticipated contributions to the company's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) announced its participation at the Jefferies Healthcare Conference, scheduled for June 10, 2022, at 11:00 a.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will outline the company's vision, goals, and capital allocation strategies. The event will be webcast live and archived for viewing on their investor relations page within 24 hours. Quest Diagnostics provides diagnostic insights to improve health outcomes for over one-third of adult Americans, maintaining a significant presence in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
-
Rhea-AI Summary

Quest Diagnostics (DGX) announced that its Senior VP and Chief Human Resources Officer, Cecilia McKenney, received the "CHRO Lifetime Achievement Award" from SharedXpertise Media. Recognized for her leadership during the COVID-19 pandemic, McKenney has championed initiatives promoting employee well-being and inclusion since joining the company in 2018. CEO Steve Rusckowski praised her empathetic leadership style, highlighting her positive impact on the organization. The award celebrates CHROs who drive innovation and excellence in employee engagement and retention, further emphasizing the importance of strong HR leadership in business growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, scheduled for payment on July 20, 2022. Shareholders of record as of July 6, 2022 will receive this dividend. This distribution reflects the company’s commitment to returning value to its investors.

Quest Diagnostics is a leader in diagnostic services, serving one in three adult Americans and half of U.S. physicians and hospitals. Its insights aim to improve health outcomes and healthcare management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
dividends
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) will present at the UBS 2022 Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will discuss the company's vision and capital strategies. The event will be available via live webcast on the company's investor relations page and archived for later viewing until June 23, 2022. Quest Diagnostics is a leader in diagnostic information services, supporting health improvements for a significant portion of the U.S. population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences

FAQ

What is the current stock price of Quest Diagnostics (DGX)?

The current stock price of Quest Diagnostics (DGX) is $153.42 as of December 24, 2024.

What is the market cap of Quest Diagnostics (DGX)?

The market cap of Quest Diagnostics (DGX) is approximately 17.1B.

What does Quest Diagnostics do?

Quest Diagnostics provides diagnostic testing, information, and services that help healthcare providers and patients make informed health decisions. The company offers a broad range of tests and diagnostic insights derived from the world’s largest database of clinical lab results.

How many people does Quest Diagnostics serve annually?

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States each year.

What are some recent achievements of Quest Diagnostics?

Recently, Quest Diagnostics has partnered with PathAI to enhance its AI and digital pathology capabilities. The acquisition of PathAI Diagnostics' digital laboratory will serve as a new AI and digital R&D center, improving cancer diagnosis quality and efficiency.

What kind of tests does Quest Diagnostics offer?

Quest Diagnostics offers over 3,000 different tests, including clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

What is the company's approach to innovation?

Quest Diagnostics focuses on incorporating AI and digital technologies into its diagnostic services to enhance accuracy, efficiency, and accessibility of its offerings. The company also pilots new technologies and expands its capabilities through strategic partnerships and acquisitions.

How extensive is Quest Diagnostics' clinical testing network?

Quest Diagnostics operates an extensive clinical testing network with approximately 2,300 patient service centers, as well as numerous doctor’s offices and hospitals across the United States.

What role do partnerships play at Quest Diagnostics?

Partnerships, such as the recent collaboration with PathAI, play a crucial role in Quest Diagnostics' strategy to integrate advanced technologies and expand its capabilities in specialized diagnostic services.

How does Quest Diagnostics contribute to healthcare management?

Quest Diagnostics provides diagnostic insights that help identify and treat diseases, inspire healthy behaviors, and improve healthcare management. These insights support more informed decision-making by both patients and healthcare providers.

What are the company’s future plans?

Quest Diagnostics plans to continue expanding its capabilities in AI and digital pathology, enhance its clinical testing services, and maintain its leadership in diagnostic information services. The company aims to leverage its diagnostic insights to empower better healthcare outcomes globally.

How does Quest Diagnostics ensure the quality of its services?

Quest Diagnostics employs nearly 50,000 dedicated professionals, including about 900 M.D.s and Ph.D.s, and integrates cutting-edge technology and rigorous quality control measures across its operations to ensure high-quality diagnostic services.

Quest Diagnostics Inc.

NYSE:DGX

DGX Rankings

DGX Stock Data

17.12B
111.10M
0.43%
91.55%
2.32%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SECAUCUS